Strategic Collaboration Vibalogics is now part of Recipharm and recently partnered with Fusix Biotech to advance next-generation cancer immunotherapies using oncolytic virus technology, signaling potential for shared CDMO opportunities in viral vectors, oncolytics, and gene therapy manufacturing.

Virotherapy Expertise With a broad service offering from GMP banking to fill finish and stability studies and experience with live viruses, vectors, vaccines, and gene therapy, there are multiple entry points for expanding engagements in early-to-late stage virotherapy programs.

Clinical-to-Commercial Scale Capabilities cover process development, tech transfer, GMP manufacturing, and lot release across drug substance and product, presenting a path to scale collaborations from clinical development to commercial supply for virotherapy and vaccine programs.

Regulatory & Quality Emphasis on robust quality systems and global regulatory compliance can be leveraged to pursue opportunities with risk-averse partners seeking dependable CDMO partners for regulated virotherapy products and complex biologics.

Growth Signals The company’s relatively small headcount but affiliation with a global CDMO network alongside recent high-profile collaborations suggests a scalable model for targeted partnerships, expanded service packages, and co-development opportunities in viral medicines and immunotherapies.